GSK's Role in FDA Effort for Autism-Related Condition Therapy
The CEO of GSK, Emma Walmsley, stated that the company has had a minimal role in the FDA's effort to approve a long-shelved drug for a condition associated with autism.
"We have no commercial interest, we have no scientific research, and we're not pursuing it,"
She described the FDA's request to update the prescribing information for the decades-old therapy leucovorin as "an administrative request".
- GSK has no commercial interest in the therapy.
- No scientific research is being conducted by GSK.
- The company is not pursuing the therapy.
Author's summary: GSK plays down its role in FDA effort.